Continuing to deny Medicare coverage for beta amyloid positron emission tomography scans that could help clarify causes of dementia is jeopardizing patient access to care and “threatens to stifle further innovation,” a patient advocacy group says.
USAgainstAlzheimer’s, a Washington, D.C.-based advocacy organization seeking to end Alzheimer’s disease by 2020, told CMS in Nov
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?